BILLERICA, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
insulin pump technology with its Omnipod® Insulin
Management System, today announced the appointments of Michael R.
Minogue and James C. Mullen to the Company's Board of Directors. Insulet
also announced that Regina Sommer and Joseph Zakrzewski have retired
from the Company's Board of Directors.
This Smart News Release features multimedia. View the full release here:
"We are delighted to welcome Mike and Jim to the Insulet Board," said
Patrick Sullivan, Chairman and Chief Executive Officer. "Both are
accomplished executives with impressive track records in the healthcare
and biotech industries. They bring global leadership experience to
Insulet and are outstanding and highly-complementary additions to the
Board as we execute our global strategic growth initiatives."
Mr. Sullivan continued, "Insulet has been well served by Reggie's and
Joe's long-standing dedication and contributions. Their active
engagement throughout their tenure has advanced the Company's growth and
success, and we sincerely thank them for their years of valued service."
About Michael R. Minogue:
Mr. Minogue is the Chief Executive Officer, President and Chairman of
Abiomed Inc., a global leader in healthcare technology and innovation. A
seasoned business executive with more than two decades of experience, he
joined Abiomed from GE Healthcare, where he holds three patents and
spent 11 years developing expertise in sales, marketing, product
development, information technologies and software/service operations.
He currently serves on the Board of Directors of AdvaMed, is the
Chairman of the Medical Device Innovation Consortium, and serves as the
Chairman of the Governor's Advisory Council on Veterans' Services for
the Commonwealth of Massachusetts. He is also on the Board of Managers
for Bioventus LLC and recently stepped down from his position as
Chairman after concluding ten years of service on the Board of Directors
for MassMEDIC. Mr. Minogue is the Co-Founder and Chairman of the
Mentoring Veterans Program (MVPvets), a nonprofit organization that
helps military veterans network with industry mentors to discover career
opportunities in the life sciences industries. He served as an Infantry
officer in the U.S. Army, which included multiple distinctions,
including Airborne Ranger, Desert Storm Veteran and he was awarded the
Bronze Star. Mr. Minogue received a BS, Engineering Management from the
United States Military Academy at West Point and an MBA from the
University of Chicago.
About James C. Mullen:
Mr. Mullen, a 30-year veteran of the biotech industry, is Chief
Executive Officer of Patheon N.V., a leading global provider of
pharmaceutical development and manufacturing services, which recently
announced an agreement to be acquired by Thermo Fisher Scientific Inc.
Prior to joining Patheon, from 2003 to 2010, Mr. Mullen served as Chief
Executive Officer and President at Biogen, one of the world's largest
biotechnology companies. Mr. Mullen held various operating positions at
Biogen prior to becoming Chief Executive Officer, including Vice
President, Operations, as well as several key manufacturing and
engineering positions, and spent over nine years at SmithKline Beecham.
His areas of expertise include biotechnology, pharmaceuticals, specialty
chemicals, manufacturing, engineering, sales and marketing. He
previously served on the Board of Directors of PerkinElmer and also as
Chairman of the Biotechnology Innovation Organization. Mr. Mullen
received a BS, Chemical Engineering from Rensselaer Polytechnic
Institute and an MBA from Villanova University.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes easier.
Insulet seeks to expand the use of insulin pump therapy with its Omnipod
Insulin Management System among people with insulin-dependent diabetes.
The Omnipod System is a revolutionary and easy-to-use tubeless insulin
pump that provides up to three days of non-stop insulin delivery,
without the need to see or handle a needle. Insulet's Delivery Systems
business partners with global pharmaceutical and biotechnology companies
to adapt the Omnipod technology platform for the delivery of
subcutaneous drugs across multiple therapeutic areas. Founded in 2000,
Insulet Corporation is based in Billerica, Massachusetts. For more
information, please visit: http://www.myomnipod.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170810005727/en/
Investor Relations and Media Contact:
Deborah R. Gordon, 978-600-7717
Investor Relations and Corporate Communications
Source: Insulet Corporation
News Provided by Acquire Media